HOME › COMPANIES › NEWAMSTERDAM PHARMA NV
EMERGING PUBLIC BIOTECH

NEWAMSTERDAM PHARMA NV (NAMS)

Naarden, Netherlands · Europe
CARDIOVASCULAR
METABOLIC
EMERGING PUBLIC BIOTECH
HEADQUARTERS
Naarden, Netherlands
TICKER
NAMS
SEGMENT
Emerging Public Biotech
THERAPY AREAS
Cardiovascular, Metabolic
KEY PRODUCTS
PRODUCTDETAILS
Obicetrapib—
COMPANY OVERVIEW

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NEWAMSTERDAM PHARMA NV — FULL INTELLIGENCE

Live regulatory signals, patent cliffs, financials, tariff exposure and pipeline — all free on PharmaSignal.

OPEN PLATFORM →